An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Withdrawn before enrolling · Phase 2

Conditions studied: Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction

In brief

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

Key facts

Study ID

NCT03704077

Run by

Bristol-Myers Squibb

People needed

0

Starts

2019-10-31

Expected to finish

2024-09-30

Last updated by the study team

2020-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed locally advanced or recurrent or metastatic GC or GEJ adenocarcinoma that is considered incurable by local therapies such as radiation or surgery
• Evidence of progressive disease (PD) on at least one prior platinum- and fluoropyrimidine-containing chemotherapy regimen
• Available tumor tissue for biomarker analysis

You may not qualify if…

• Must not have squamous cell or undifferentiated GC or GEJ
• Untreated known central nervous system (CNS) metastases
• Uncontrolled or significant cardiovascular disease
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution — Bakersfield, California, United States
• Local Institution — Fullerton, California, United States
• Local Institution — Los Angeles, California, United States
• Local Institution — Redondo Beach, California, United States
• Local Institution — Santa Barbara, California, United States
• Local Institution — Aurora, Colorado, United States
• Local Institution — Lakewood, Colorado, United States
• Local Institution — Miami, Florida, United States
• Local Institution — Tampa, Florida, United States
• Local Institution — Marietta, Georgia, United States
• Local Institution — Boston, Massachusetts, United States
• Local Institution — St Louis, Missouri, United States
• Local Institution — New Brunswick, New Jersey, United States
• Local Institution — Chapel Hill, North Carolina, United States
• Local Institution — Charlotte, North Carolina, United States
• Local Institution — Fargo, North Dakota, United States
• Local Institution — Allentown, Pennsylvania, United States
• Local Institution — Sioux Falls, South Dakota, United States
• Local Institution — Vancouver, Washington, United States
• Local Institution — Viedma, Río Negro Province, Argentina
• Local Institution — Buenos Aires, Argentina
• Local Institution — Buenos Aires, Argentina
• Local Institution — CABA, Argentina
• Local Institution — Córdoba, Argentina
• Local Institution — Daphne, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.